MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: alemtuzumab
Biological: rituximab
Drug: pentostatin
Drug: sargramostim

First Posted Date: 2008-04-30

Last Posted Date: 2014-07-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 41

Registration Number: NCT00669318

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Faculty Development to Improve Mini-CEX Ratings

Not Applicable

Completed

Conditions: Faculty Development

Interventions: Behavioral: Rater training workshop

First Posted Date: 2008-04-28

Last Posted Date: 2008-04-28

Lead Sponsor: Mayo Clinic

Target Recruit Count: 52

Registration Number: NCT00667940

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed

Conditions: Breast Cancer
Depression
Hot Flashes
Psychosocial Effects of Cancer and Its Treatment

First Posted Date: 2008-04-25

Last Posted Date: 2024-08-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 85

Registration Number: NCT00667121

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 1 locations

Over Active Bladder Instillation Study - Botox

Phase 3

Terminated

Conditions: Urinary Urge Incontinence
Detrusor Hyperreflexia
Urge Incontinence
Urinary Incontinence
Overactive Bladder

Interventions: Drug: DMSO Instillation
Drug: Botox Instillation

First Posted Date: 2008-04-25

Last Posted Date: 2014-07-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT00667095

Locations: 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States

Combination Chemotherapy in Treating Patients With Sarcoma

Early Phase 1

Completed

Conditions: Ovarian Cancer
Sarcoma

First Posted Date: 2008-04-21

Last Posted Date: 2018-10-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 28

Registration Number: NCT00662233

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Acamprosate: Genes Associated With Response

Completed

Conditions: Alcoholism

Interventions: Drug: acamprosate

First Posted Date: 2008-04-21

Last Posted Date: 2013-03-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 485

Registration Number: NCT00662571

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dasatinib
Drug: lapatinib ditosylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-04-21

Last Posted Date: 2017-03-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 27

Registration Number: NCT00662636

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Phase 3

Completed

Conditions: Anemia
Leukemia
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Precancerous Condition

Interventions: Biological: darbepoetin alfa
Other: placebo
Drug: sodium ferric gluconate complex in sucrose
Dietary Supplement: ferrous sulfate

First Posted Date: 2008-04-21

Last Posted Date: 2011-05-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 502

Registration Number: NCT00661999

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin

Completed

Conditions: Anticoagulation in Dialysis Patients

First Posted Date: 2008-04-17

Last Posted Date: 2023-03-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 37

Registration Number: NCT00660946

Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2008-04-15

Last Posted Date: 2017-05-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 7

Registration Number: NCT00658892

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy